Search VRTX
Vertex Pharmaceuticals Incorporated
NasdaqGS · CIK 875320
Last close504.73
Daily change-2.01 (-0.40%)
10 Years gain+481.55%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
VRTX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
63.7Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue18
Quarterly Revenue78
Annual CFO18
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth12.9 / 25
Quality12.1 / 25
Capital Efficiency11.6 / 20
Balance Sheet15.0 / 15
Shareholder Economics8.9 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 43.9808 percentage points.
ROIC expansionROIC improved by 40.4997 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 1.657%.
Key Metrics
Revenue Growth TTM13.64%OK
Revenue CAGR 3Y10.35%OK
Gross Margin86.21%OK
Operating Margin38.2%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC33.82%OK
Incremental Operating Margin 3Y36.32%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-1.66%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $12.00B | $10.35B | $4.17B | $3.63B | $3.19B | 86.24% | 34.77% | 26.61% | 31.79% | 258M |
| 2025 FY Dec 31, 2024 | $11.02B | $9.49B | -$232.90M | -$492.60M | -$790.30M | 86.11% | -2.11% | -7.17% | -1.82% | 257.9M |
| 2025 FY Dec 31, 2023 | $9.87B | $8.61B | $3.83B | $3.54B | $3.34B | 87.21% | 38.83% | 33.81% | 66.7% | 260.5M |
| 2024 FY Dec 31, 2022 | $8.93B | $7.85B | $4.31B | $4.13B | $3.93B | 87.9% | 48.23% | 43.95% | 118.43% | 259.1M |
| 2023 FY Dec 31, 2021 | $7.57B | $6.67B | $2.78B | $2.64B | $2.41B | 88.06% | 36.73% | 31.8% | 103.69% | 259.9M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $12.36B | sum latest 4 fiscal quarters Revenue | OK | 0000875320-26-000259, 0000875320-25-000232 |
| Revenue Growth TTM | 13.64% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000875320-26-000259, 0000875320-25-000232 |
| Revenue CAGR 3Y | 10.35% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000875320-26-000056 |
| Revenue CAGR 5Y | 14.1% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000875320-26-000056 |
| Gross Profit CAGR 3Y | 9.65% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000875320-26-000056 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000875320-26-000259, 0000875320-25-000232 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 86.21% | Gross Profit / Revenue | OK | 0000875320-26-000259, 0000875320-25-000232 |
| Operating Margin | 38.2% | Operating Income / Revenue | OK | 0000875320-26-000259, 0000875320-25-000232 |
| ROIC | 33.82% | NOPAT / Average Invested Capital | OK | 0000875320-26-000259, 0000875320-25-000232 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000875320-26-000259 |
| Current Ratio | 3.19x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $48.44 | Revenue / Diluted Shares | OK | 0000875320-26-000259, 0000875320-25-000232 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |